For the year ending 2025-12-31, XRAY had $54M increase in cash & cash equivalents over the period. $104M in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net loss | -598 | -910 | -132 | -950 |
| Depreciation | 141 | 133 | 132 | 119 |
| Amortization of intangible assets | 211 | 216 | 211 | 209 |
| Fixed asset impairment | - | - | - | 0 |
| Goodwill impairment | 525 | 773 | 291 | 1,187 |
| Intangible asset impairment | 125 | 241 | 16 | 100 |
| Deferred income taxes | 30 | -136 | -130 | -228 |
| Stock-based compensation expense | 33 | 39 | 46 | 59 |
| Restructuring and other costs | - | - | 33 | - |
| Equity in earnings from unconsolidated affiliates | - | 0 | -4 | -36 |
| Other non-cash (income) expense | 10 | 9 | 5 | -60 |
| Loss (gain) on sale or disposal of non-strategic businesses and product lines | - | - | 0 | -3 |
| Loss (gain) on disposal of property, plant and equipment | 0 | -19 | - | - |
| Accounts and notes receivable-trade, net | 91 | -104 | 58 | -85 |
| Inventories, net | 17 | -17 | -6 | 141 |
| Prepaid expenses and other current assets | 7 | -38 | 58 | 33 |
| Other noncurrent assets | 7 | 5 | -4 | -1 |
| Accounts payable | 11 | -30 | 14 | 30 |
| Accrued liabilities | -74 | -39 | -16 | -6 |
| Income taxes | -32 | 38 | -11 | -15 |
| Other noncurrent liabilities | -5 | -28 | 30 | 1 |
| Net cash provided by operating activities | 235 | 461 | 377 | 517 |
| Cash paid for acquisitions of businesses and equity investments, net of cash acquired | - | - | 0 | 0 |
| Cash received on sale of non-strategic businesses or product lines | 0 | 0 | 13 | 0 |
| Capital expenditures | 131 | 180 | 149 | 149 |
| Cash received on derivative contracts | 10 | 1 | 39 | 13 |
| Proceeds from sale of property, plant and equipment | - | - | 7 | - |
| Cash paid on derivative contracts | 14 | 12 | - | - |
| Other investing activities, net | -3 | 6 | -1 | 2 |
| Net cash used in investing activities | -132 | -197 | -89 | -138 |
| Proceeds from long-term borrowings | 553 | 1 | 0 | - |
| Proceeds from long-term borrowings, net of deferred financing costs | - | - | - | 6 |
| Cash paid for deferred financing costs | 16 | - | - | - |
| Repayments on long-term borrowings | 147 | 88 | 7 | 2 |
| Net borrowings on short-term borrowings | - | 177 | 126 | -64 |
| Proceeds from 364-day bridge loan | 435 | - | - | - |
| Payments on terminated derivative instruments | - | - | - | 0 |
| Repayment of 364-day bridge loan | 435 | - | - | - |
| Proceeds from exercised stock options | - | - | 0 | 6 |
| (repayments) proceeds on other short-term borrowings, net | -336 | - | - | - |
| Cash paid for treasury stock | 0 | 250 | 300 | 150 |
| Cash dividends paid | 128 | 126 | 116 | 104 |
| Other financing activities, net | -6 | -16 | -10 | -21 |
| Net cash used in financing activities | -80 | -302 | -307 | -329 |
| Effect of exchange rate changes on cash and cash equivalents | 31 | -24 | -12 | -24 |
| Net (decrease) increase in cash and cash equivalents | 54 | -62 | -31 | 26 |
| Cash and cash equivalents at beginning of period | 272 | 334 | 365 | 339 |
| Cash and cash equivalents at end of period | 326 | 272 | 334 | 365 |
DENTSPLY SIRONA Inc. (XRAY)
DENTSPLY SIRONA Inc. (XRAY)